Jed provides transactional counseling in relation to intellectual property issues that arise in a wide range of corporate transactions. Leveraging a deep understanding of intellectual property law and commercial sensibilities across a variety of industries, Jed advises clients on stand-alone licensing arrangements, the acquisition and sale of privately and publicly owned companies, and the formation of joint ventures and technology collaborations within the United States and across borders. Clients regularly call on Jed to lead the complex negotiations of IP provisions necessary to implement these transactions and to manage the related diligence processes. He has supported deals across a wide range of industries, including in the automotive, nuclear power, medical device, computing and telecommunications, health care, and consumer products industries.
Jed also advises clients regarding strategic patent portfolio development and counsels them in relation to patent enforcement strategies and defense against threatened patent infringement litigation. Jed has drafted and prosecuted patent applications in the fields of computer networking, wireless networking, video displays, medical devices, speech processing, MEMS devices, business methods, semiconductor processing, optical devices, video surveillance and software.
While in law school, Jed was a contributing editor for the Michigan Law Review. He also participated in the Jessup International Law Moot Court.
Advised AP Intego, a fast-growing digital insurance agency, on the sale of its business to Next Insurance.
Advised pharmaceutical company Charles River Laboratories on the IP diligence related to its strategic partnerships with Valence (formerly InVivo AI) and Cypre.
Represented Allscripts Healthcare Solutions, Inc. in relation to the IP issues arising from the $1.35 billion sale of its CarePort business to Wellsky, Inc., a global health and community care technology company.
Led IP diligence in private equity firm Gemspring Capital’s multimillion dollar acquisition of a leading web-based EHR / electronic health billing systems company.
Co-led IP diligence team advising CVS on its $69 billion merger with Aetna.
Represented Mitsubishi Heavy Industries (MHI) in relation to IP issues arising from MHI’s participation in the reorganization of the French Nuclear Industry, including renegotiating the IP terms of the restructured, Franco-Japanese joint venture, ATMEA, dedicated to developing, licensing, and selling the mid-size 1100 MWe ATMEA-1 pressurized water nuclear reactors around the world.
Represented LG Chem (via Lee & Ko) on IP aspects of their acquisition of the DuPont’s Soluble OLED technology.
Negotiated the IP acquisition and licensing provisions of an acquisition by a private equity-backed strategic buyer of an enterprise solutions business out of a bankrupt telecommunications giant.
Advised a multinational automation systems provider on the IP provisions of its collaboration agreement with a company focused on engineering technologies for autonomous driving.
Do not send any information or documents that you want to have treated as secret or confidential. Providing information to McDermott via email links on this website or other introductory email communications will not create an attorney-client relationship; will not preclude McDermott from representing any other person or firm in any matter; and will not obligate McDermott to keep confidential the information you provide. McDermott cannot enter into an attorney-client relationship with you until McDermott has determined that doing so will not create a conflict of interest and until you and McDermott have entered into a written agreement or engagement letter that sets forth the terms of our relationship.